Skip to main content
Delfa

← Trials/Trial dossier/NCT01072812

TerminatedPhase 1

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment

Lead sponsor

Annovis Bio Inc.

Asset

Buntanetap

Listed sites

1

Recruiting sites

-

Enrollment

5

actual

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criterion

MMSE ≥24

Primary endpoints

PharmacokineticsPharmacodynamics

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01072812
Org study IDQR 12001

Timeline

Milestones

Study start2010-02 (month precision)
Study first posted2010-02-22estimated
Primary completion2010-07actual (month precision)
Study completion2010-07actual (month precision)
Last update posted2015-04-22estimated

Assets

Drug assets

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age55 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Males or post-menopausal females aged 55 to 80 years, inclusive.

2. Must have Mild Cognitive Impairment (MCI) (amnestic subtype) according to Petersen's criteria (2004).

3. Mini Mental Status Examination (MMSE) score should be ≥24.

4. Must score below a pre-determined cut-off score on the logical memory II delayed paragraph recall sub-test of the Wechsler Memory Scale Revised (WMS-R).

5. Must have a Clinical Dementia Rating of 0.5 with a memory box score of 0.5 or 1.0.

6. Modified Hachinski score of less than or equal to 4.

7. Hamilton Depression rating scale (HAMD17) score of less than or equal to 12 with a score of 0 on items 1, 2, and 3 (depressed mood, feelings of guilt, and suicidal ideation).

8. No evidence of current suicidal ideation or previous suicide attempt in past 2 years as evaluated in the Columbia Suicidality Checklist.

9. MRI scans within 12 months prior to screening, or per screening MRI, without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease.

10. No clinically significant abnormalities in the lumbar spine should be present on a lumbar X-ray that would contraindicate lumbar puncture.

11. Adequate visual and hearing ability (physical ability to perform all the study assessments).

12. Normal B12, folic acid, and thyroid function tests (thyroid stimulating hormone [TSH], free T4, and free T3).

13. Do not require nursing home care

Exclusion criteria

1. Any significant neurologic disease other than amnestic MCI, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.

2. Major depression, schizophrenia or another major psychiatric disorder as described in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within the past 2 years.

3. Psychotic features, agitation, or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.

4. History of alcohol or substance abuse or dependence within the past 2 years.

5. Subjects with any febrile illness within 1 week prior to the CSF collection.

6. Subjects who have history of migraine headaches and any other type of headaches of at least moderate severity more than twice per month.

7. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol or pose potential risk to the subjects.

8. Use of medications prohibited by the study.

9. Any clinically significant laboratory abnormalities.

10. Subjects with infection or inflammation of the skin or skin disease at or in proximity to the lumbar puncture site.

11. History of lumbar spine surgery or chronic low back pain (CLBP).

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Amyloid biomarkers
1
Tau biomarkers
1
Fluid / digital biomarkers
1
Safety / tolerability / PK
1

Amyloid biomarkers

1 endpoint
Primary/protocol endpoint

Pharmacodynamics

Time frame:10 days

descriptive

Tau biomarkers

1 endpoint
Secondary/protocol endpoint

Biomarkers

Time frame:10 days

descriptive

Fluid / digital biomarkers

1 endpoint
Primary/protocol endpoint

Pharmacokinetics

Time frame:10 days

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Safety

Time frame:10 days

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.